NPM1 and acute myeloid leukemia: In particular, the unique C-terminal sequences of mutated NPM1 in NPM1-mutant AML have been investigated as potential leukemia specific antigens that may elicit endogenous T cell responses and could also serve as targets for immunotherapy.